ADMA Biologics receives FDA approval for a process enhancing plasma production yields by 20%, boosting growth and capacity for its products. ADMA Biologics, Inc. has announced the U.S. FDA approval of ...

ADMA announced the FDA's approval of its yield enhancement process. The company's yield enhancement process has demonstrated the ability to increase production yields by approximately 20%.

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the ...

ADMA reaffirmed its previously provided financial guidance for both 2025 and 2026. For 2025, management expects total revenue of $500 million or more, adjusted EBITDA of at least $235 million, and ...

--ADMA Biologics, Inc., a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced U.S. FDA approval of its ...